ClinicalTrials.gg
CompletedNCT05658510Updated Aug 7, 2026

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)

A Phase 3 interventional study of BXCL501 and Matching Placebo in Agitation,Psychomotor, Bipolar I Disorder and Bipolar II Disorder, sponsored by BioXcel Therapeutics Inc. Completed at 24 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by BioXcel Therapeutics Inc · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
452
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies testing dexmedetomidine in Psychomotor Agitation — 5 open to participants now, 5 under way, 2 of them phase 3. Dexmedetomidine · Psychomotor Agitation.

Enrollment
Largest of 32
452 · median 73
Started
2022
with 4 others
Phase 3
7 of 32
none open now
Registered
24th of 32
by date
Lead sponsor
11 of 32
BioXcel Therapeutics Inc

Among the 32 studies testing dexmedetomidine in Psychomotor Agitation, this one has the largest enrollment, is one of 5 that started in 2022, is one of 7 in phase 3, and was the 24th registered.

Psychomotor Agitation

231 studies on the registry are indexed under Psychomotor Agitation; 28 are open to participants now.

Browse Psychomotor Agitation studies →

Open to participants now

5 of the 32 studies testing dexmedetomidine in Psychomotor Agitation are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About dexmedetomidine

Dexmedetomidine: first FDA approval 1999 (PRECEDEX), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Psychomotor Agitation studies recruiting now, 8 (40%) set no upper age limit and 7 (35%) stop at 75 or younger; 4 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies testing dexmedetomidine in Psychomotor Agitation, or all of them as a file.
02

Study summary

In this study, an investigational medication named BXCL501 is being tested for the treatment of episodes of agitation associated with bipolar I and bipolar II disorder, schizophrenia, schizoaffective and schizophreniform disorder. This study compares the study drug to a placebo.

Read the detailed description

This is a randomized, double-blind, placebo-controlled, 2-Part, Phase III study to assess the efficacy, safety, and tolerability of BXCL501 in adult (18-75 years old) males and females with agitation episodes associated with a primary diagnosis of bipolar I disorder, bipolar II disorder, schizophrenia, schizoaffective disorder, or schizophreniform disorder. Part 1 of the study is a one-day, in-clinic treatment of 60 mcg dose, and post-treatment observation period with patients experiencing an acute episode of agitation. Part 1 is now complete. Part 2 of the study is a 12-week study to determine the safety of a BXCL501 120 mcg dose when used as needed for episodes of agitation at home.

03

Conditions studied

  • Agitation,Psychomotor
  • Bipolar I Disorder
  • Bipolar II Disorder
  • Schizophrenia
  • Schizoaffective Disorder
  • Schizophreniform Disorders
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

A patient may enroll in only one part of the study; either Part 1 or Part 2.

Inclusion criteria

Inclusion Criteria:

  • Male and female patients between the ages of 18 to 75 years, inclusive
  • Patients who can read, understand and provide written .
  • Patients who have met Diagnostic and Statistical Manual5/5-Text Revision criteria for bipolar I or bipolar II disorder, schizophrenia, schizoaffective or schizophreniform disorder.
  • Patients who, in the opinion of the Principal Investigator, are in good general health before study participation based on a detailed medical history, a physical examination, a 12-lead , a blood chemistry profile, hematology, and urinalysis.
  • Participants who agree to use a medically acceptable and effective method

Part 1 only

  • Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥ 14 on the 5 items (poor impulse control, tension, hostility, uncooperativeness, and excitement) comprising the PEC.
  • Patients with a score of ≥4 on at least 1 of the 5 items on the PEC at Baseline.

Part 2 only

  • Patients have had at least three clinical presentations of agitation requiring an intervention (e.g., receipt of as needed [PRN] medication for the episode, clinic visit, emergency room visit, emergency medical services intervention, law enforcement intervention) in the past three months prior to Screening
  • Patients who are receiving stable psychotropic treatment for 30 days prior to Screening for the underlying primary diagnosis and who are expected to remain on stable treatment for the duration of the study.
  • The patient can understand and follow the study procedures, including completing the Agitation Episode Diary.

Exclusion criteria

Exclusion Criteria:

  • Patients with serious or unstable medical illnesses. These include current hepatic (moderate-severe hepatic impairment), renal, gastroenterological, respiratory, cardiovascular (including ischemic heart disease, congestive heart failure), endocrinologic, or hematologic disease.
  • A history of agitation episodes due to substance use.
  • A diagnosis of antisocial personality disorder, borderline personality disorder, or narcissistic personality disorder that predated the diagnosis of schizophrenia or bipolar disorder
  • Patients who are judged to be at significant risk of suicide
  • Female patients who have a positive pregnancy test at Screening or Baseline, or are breastfeeding.
  • Patients currently treated with alpha-1 noradrenergic blockers (terazosin, doxazosin, tamsulosin, alfuzosin, or prazosin), alpha-2 adrenergic agonists, or other prohibited medications.
  • Patients with hydrocephalus, seizure disorder, or history of significant head trauma, stroke, , subarachnoid bleeding, brain tumor, encephalopathy, meningitis, Parkinson's disease, or focal neurological findings.
  • History of syncope or other syncopal attacks, current evidence of hypovolemia, or orthostatic hypotension
  • Patients with laboratory or abnormalities considered by the Investigator
  • Patients who have received an drug within 30 days before the study start
  • Patients who have previously received BXCL501 via prescription (under the trade name IGALMI™) or received BXCL501 in clinical trial
  • Patients considered by the Investigator to be unsuitable candidates for receiving dexmedetomidine or considered to be unsuitable for participating in the study for any reason.

Part 1 only

  • Patients with agitation caused by acute intoxication, including identification of alcohol by breathalyzer or drugs of abuse (except for THC) during urine screening.
  • Use of benzodiazepines or other hypnotics or antipsychotic drugs in the 4 hours before study treatment.

Part 2 only

  • Psychiatric comorbidities are generally allowed; however, moderate or severe substance use disorders (SUD) (within the past 6 months) are exclusionary if the substance involved is other than nicotine or caffeine. Cannabis use is not exclusionary if it is not the focus of treatment in the last 6 months before Screening.
  • Self-injurious behavior that is active.
  • Patients with known personal or family history of genetic long syndrome.

Informant Inclusion Criteria:

  • At least 18 years of age at the time of screening.
  • Is a spouse, significant other, family member, friend, or home health aide, residence manager of an adult patient who is determined to be eligible for the study per the patient inclusion/exclusion criteria.
  • Has known the patient for at least 3 months cumulatively.
  • Currently living with or routinely contacting the patient at least five days a week.
  • Does not plan to discontinue contact with the patient during the study period.
  • Willing and able to provide written .
  • Willing and able to follow the study procedures, including completing the Agitation Episode Diary and other study procedures during the study.
  • Willing and able to accompany patient and remain present at the clinical site during the clinic visits and be interviewed by the Investigator.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
452 participants (actual)

Study arms

  • Experimental
    Part 1: 60 mcg of BXCL501

    Sublingual film containing 60 Micrograms Dexmedetomidine

    Drug: BXCL501

  • Placebo comparator
    Part 1: Matching Placebo

    Sublingual Placebo film

    Drug: Matching Placebo

  • Experimental
    Part 2: 120 mcg of BXCL501

    Sublingual film containing 120 Micrograms Dexmedetomidine

    Drug: BXCL501

  • Placebo comparator
    Part 2: Matching Placebo

    Sublingual Placebo film

    Drug: Matching Placebo

Interventions

  • Sublingual Film

    Also known as: Dexmedetomidine

  • DrugMatching Placebo

    Sublingual Placebo Film

    Also known as: Placebo

06

What researchers measure

Primary outcomes

  1. Part 1: Change from baseline in Positive and Negative Syndrome Scale - Excited (PEC) total score

    The Positive and Negative Syndrome Scale - Excited Component (PEC) comprises 5 items associated with agitation: poor impulse control, tension, hostility, uncooperativeness, and excitement; each scored 1 (minimum) to 7 (maximum). The PEC, the sum of these 5 subscales, thus ranges from 5 (absence of agitation) to 35 (extremely severe)

    Time frame: 2 hours

  2. Part 2: The incidence of SAEs and TEAEs compared with placebo.

    To assess the safety of 120 mcg BXCL501 when used in an at-home environment based on serious adverse events (SAE) and treatment emergent adverse events (TEAEs).

    Time frame: Through study completion, an average of 12 weeks

Secondary outcomes

  1. Part 1: Clinical Global Impression - Improvement (CGI-I)

    The Clinical Global Impression - Improvement (CGI-I) for agitation in response to treatment measures the current level of agitation relative to the level of agitation prior to administration of study intervention. The CGI-I scores range from 1 to 7 with a score of 1 indicating very much improved, and a score of 7 indicating very much worse.

    Time frame: 2 hours

  2. Part 1: Change in Modified Clinical Global Impression - Severity (mCGI-S) scores from Baseline

    The Modified Clinical Global Impression - Severity (mCGI-S) measures the current level of agitation. For this study, the mCGI-S is a 4-point scale where a score of 0 represents no agitation, and scores of 1-3 describe increasing severities of agitation (mild, moderate, severe).

    Time frame: 2 hours

  3. Part 1:The number of responders based on the Modified Clinical Global Impression - Severity (mCGI-S) score

    The Modified Clinical Global Impression - Severity (mCGI-S) measures the current level of agitation. A responder is characterized as a participant with a score of 0 (represents no agitation) or 1 (mild agitation)

    Time frame: 2 hours

  4. Part 1:Change from baseline in Agitation-Calmness Evaluation Scale (ACES)

    The Agitation-Calmness Evaluation Scale (ACES) is a single item scale that measures overall agitation and sedation, where a score of 1 indicates marked agitation; 2 - moderate agitation; 3 - mild agitation; 4 - normal behavior; 5 - mild calmness; 6 - moderate calmness; 7 - marked calmness; 8 - deep sleep; and 9 - unarousable.

    Time frame: 2 hours

  5. Part 1: Incidence of treatment-emergent adverse events (TEAEs)

    To assess the safety of BXCL501 based on treatment-emergent adverse events (TEAEs)

    Time frame: Through study completion, an average of 8 hours

  6. Part 1: Change from baseline in heart rate (HR) at rest

    The effect of BXCL501 on heart rate at rest

    Time frame: Baseline, and 2, 4, 6, and 8 hours postdose

  7. Part 1: Change from baseline in heart rate (HR) under orthostatic stress

    The effect of BXCL501 on heart rate under orthostatic stress

    Time frame: Baseline, and 2, 4, 6, and 8 hours postdose

  8. Part 1: Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) at rest

    The effect of BXCL501 on systolic and diastolic blood pressure at rest

    Time frame: Baseline, and 2, 4, 6, and 8 hours postdose

  9. Part 1: Change from baseline in systolic blood pressure (SBP) and diastolic blood pressure (DBP) under orthostatic stress

    The effect of BXCL501 on systolic and diastolic blood pressure under orthostatic stress

    Time frame: Baseline, and 2, 4, 6, and 8 hours postdose

  10. Part 1: Incidence of abnormal electrocardiograms (ECG) reported as an adverse event (AE)

    Any abnormal ECG value that is reported as an adverse event (AE)

    Time frame: Through study completion, an average of 8 hours

  11. Part 1: Incidence of abnormal clinical laboratory values reported as an adverse event (AE)

    Any abnormal clinical laboratory value that is reported as an adverse event (AE)

    Time frame: Through study completion, an average of 8 hours

  12. Part 2: Incidence of interactions with emergency services related to agitation

    Evaluate the impact of BXCL501 on the use of healthcare and emergency service resources because of agitation episodes

    Time frame: Through study completion, an average of 12 weeks

  13. Part 2: Incidence of overall adverse events and AEs leading to discontinuation

    To evaluate the safety and tolerability profile of 120 mcg BXCL501

    Time frame: Through study completion, an average of 12 weeks

07

Study locations

24 sites
  • BioXcel Clinical Research Site 113
    Bellflower, California 90706, United States
  • BioXcel Clinical Research Site 128
    Cerritos, California 90703, United States
  • BioXcel Clinical Research Site 110
    Culver City, California 90230, United States
  • BioXcel Clinical Research Site 108
    Garden Grove, California 92845, United States
  • BioXcel Clinical Research Site 117
    Lemon Grove, California 91945, United States
  • BioXcel Clinical Research Site 121
    Los Angeles, California 90015, United States
  • BioXcel Clinical Research Site 123
    Oceanside, California 92056, United States
  • BioXcel Clinical Research Site 104
    Orange, California 92868, United States
  • BioXcel Clinical Research Site 133
    Rancho Cucamonga, California 91730, United States
  • BioXcel Clinical Research Site 114
    Riverside, California 92506, United States
  • BioXcel Clinical Research Site 129
    Denver, Colorado 80209, United States
  • BioXcel Clinical Research Site 131
    Miami, Florida 33122, United States
  • BioXcel Clinical Research Site 124
    Miami, Florida 33186, United States
  • BioXcel Clinical Research Site 130
    Elgin, Illinois 60123, United States
  • BioXcel Clinical Research Site 103
    Gaithersburg, Maryland 20877, United States
  • BioXcel Clinical Research Site 118
    Las Vegas, Nevada 89102, United States
  • BioXcel Clinical Research Site 137
    Las Vegas, Nevada 89119, United States
  • BioXcel Clinical Research Site 105
    Berlin, New Jersey 08009, United States
  • BioXcel Clinical Research Site 122
    Beachwood, Ohio 44122, United States
  • BioXcel Clinical Research Site 136
    Austin, Texas 78754, United States
  • BioXcel Clinical Research Site 102
    DeSoto, Texas 75115, United States
  • BioXcel Clinical Research Site 125
    Irving, Texas 75062, United States
  • BioXcel Clinical Research Site 127
    Plano, Texas 75093, United States
  • BioXcel Clinical Research Site 126
    Everett, Washington 98201, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2022 to primary completion in Aug 2025, 32 months.

Of 23 phase 3 interventional studies under Psychomotor Agitation, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 47. This study's 32 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2022
First posted
Dec 20, 2022
StartActual
Nov 21, 2022
Primary completionActual
Aug 15, 2025
CompletionActual
Aug 15, 2025
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05658510
Lead sponsor
BioXcel Therapeutics Inc
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Dec 20, 2022
Start date
Nov 21, 2022
Primary completion
Aug 15, 2025
Completion
Aug 15, 2025
Last update
Aug 7, 2026

Study contacts

BioXcel MM
study chair · BioXcel Therapeutics

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion